EOLS News
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture PR Newswire NEW YORK, Sept. 1, 2026 NEW...
PR Newswire
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. The increasing momentum of our portfolio focus has resulted in Evolus gaining...
Business Wire
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies existing licensing and distribution agreement, providing Evolus...
Business Wire
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evolus to Report Second Quarter Financial Results on August 5, 2026
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.Evolus management will...
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the companys common stock to 38 newly hired non-executive...
Business Wire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics PR Newswire RENO, Nev., July 9, 2026 Issued on behalf of Conexeu Sciences Inc.Conexeu...
PR Newswire